Klinische und epidemiologische Daten zu Malignomen des Kopf-Hals-Bereichs

Abstract

Based on the documentation of the Munich Cancer Register our study is the first to present a detailed description of clinical and epidemiological data of patients suffering from head and neck malignomas.

Combination of surgical resection and HDR-brachytherapy in patients with recurrent or advanced head and neck carcinomas

“…The results show that HDR-BT is an effective local treatment associated with long-lasting remission in a certain subset of recurrences, and in locally advanced primary tumours. The mean survival of our patients was 26.1 months and that is much more than expected based on previous epidemiological data (Lang et al, 2002). Kolotas et al (2007) have also treated recurrent tumours by brachytherapy with and without surgery and achieved similar local survival rates of 31% after 2 years.…”

“…Both have a poor prognosis (Pericot et al, 2000). In larger cohorts, survival after local and after regional recurrence both are poor e below 20% after 2 years as shown for oropharyngeal carcinomas by Lang et al (2002) demonstrating that both are indicators of loss of disease control. Median survival after first progression of carcinomas of the lips and the oral cavity does not exceed 6e9 months (Lang et al, 2002).…”

Palliative Chemotherapie von Kopf-Hals-Tumoren: Aktueller Stand und neue Entwicklungen

“…Recent studies with monoclonal antibodies or small molecule tyrosine kinase inhibitors report on a response rate of 10 -20 %. [1]. Wegen des im Vergleich zu den meisten anderen Krebserkrankungen jüngeren Erkrankungsalters sind bei Männern von 40 -59 Jahren über 10 % aller krebsbedingten Sterbefälle auf Kopf-HalsTumore zurückzuführen [1].…”

“…Vin: Vinorelbin, Bleo: Bleomycin, MTX: Methotrexat, † ohne Nasopharynxkarzinome,1 10 Patienten neoadjuvant chemotherapiert,2 13 Patienten Radiochemotherapie, 10 Patienten OP und Radiatio, 1 Patienten Operation und Radiochemotherapie, ‡ mit/ohne Vorbehandlung,3 14 Patienten Radiochemotherapie,13 Patienten OP und Radiatio, 1 Patienten Operation und Radiochemotherapie, 9 Patienten palliative Chemotherapie,4 39 Patienten Radiochemotherapie, 27 Patienten OP, 18 Patienten palliative Chemotherapie. Erlotinib § Zulassung beantragt im August 2005 als second line-Monotherapie und in Kombination mit Bestrahlung.…”

Systemic therapy strategies for head-neck carcinomas: Current status

“…For patients with local or regionally advanced disease (Stage III or IV), the prognosis is much worse. Despite the use of intense, localised therapy, 50–60% of such patients have a local or regional recurrence after their first treatment course, and remote metastases appear in up to 20% [192], [108], [14]. For patients with uncontrolled local and regional metastases, effective systemic treatment is required (e.g.…”